Price
$14.85+356%1Y
1M+14%1Y+356%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierValue97
Quality3
Momentum94
Growth-
What they do
We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT® technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range.
In the company’s own words · 20-F filed Mar 9, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$1.01B
1Y Return+356%
5Y Return+51%
Raw charts
5 series · TTMAs reported to the SEC, without any scoring.